In-Silico Investigation of GRP78 Inhibition in Glioblastoma: Implications for Therapeutic Targeting | ||||
| Sohag Journal of Sciences | ||||
| Volume 10, Issue 2, June 2025, Page 266-273 PDF (763.93 K) | ||||
| Document Type: Regular Articles | ||||
| DOI: 10.21608/sjsci.2025.367748.1262 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mahmoud E. Rashwan   1; Mahrous R. Ahmed 1; Abdo A. Elfiky2
| ||||
| 1Physics Department, Faculty of Science, Sohag University, Sohag, 82524, Egypt | ||||
| 2Biophysics Department, Faculty of Science, Cairo University, Giza, 12613, Egypt | ||||
| Abstract | ||||
| Glioblastoma (GBM) is an aggressive, fast-growing, and treatment-resistant tumor with high recurrence and poor prognosis. GRP78 is a molecular chaperone implicated in cancer cell survival, proliferation, and stress response, and overexpression has been shown to play a role in GBM development and drug resistance. In this work, we examine Zidovudine triphosphate (ZDV-TP) as a potential GRP78 inhibitor by computational approaches, including molecular docking, molecular dynamics (MD) simulations, and MMGBSA calculations. The results indicate that ZDV-TP securely binds to and energetically favors the ATP-binding site of GRP78, suggesting that it could disrupt its chaperone function. 100 ns MD simulations show that the GRP78-ZDV-TP complex is stable without significant conformational change, implying no destabilization of the protein structure. Such findings form a foundation that ZDV-TP is effective in inhibiting GRP78 and can abolish its role in GBM tumor formation and drug resistance. Further experimental proof should be tested for ZDV-TP to be an auspicious therapeutic target of GBM. | ||||
| Keywords | ||||
| GRP78; glioblastoma; molecular dynamics simulation; molecular docking; binding energy calculation | ||||
|
Statistics Article View: 128 PDF Download: 98 |
||||
